Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies
暂无分享,去创建一个
G. Guyatt | H. Tian | Sheyu Li | B. Aertgeerts | N. Su | Heyue Du | I. Riaz | P. Vandvik | Yang Wang | Q. Hao | G. Bekkering | N. Delvaux | Safi U. Khan | Jing Li | Jing Li | Yang Wang | Shi Zhan | Ling Li | Sheyu Li
[1] G. Guyatt,et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations , 2022, BMJ.
[2] ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.
[3] Y. Ouchi,et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized Controlled Trial. , 2019, Circulation.
[4] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[5] S. Grundy,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.
[6] C. Reid,et al. Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis , 2019, Front. Pharmacol..
[7] D. Moga,et al. Statin Use and Gastrointestinal Hemorrhage: A Large Retrospective Cohort Study , 2018, American Journal of Cardiovascular Drugs.
[8] A. Jagielska,et al. Clinical management of heterozygous familial hypercholesterolemia in a Polish outpatient metabolic clinic: a retrospective observational study , 2017, Archives of medical science : AMS.
[9] Maoqin Shu,et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. , 2017, The Cochrane database of systematic reviews.
[10] G. Assmann,et al. Can LDL cholesterol be too low? Possible risks of extremely low levels , 2017, Journal of internal medicine.
[11] Hun‐Sung Kim,et al. The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG‐CoA reductase inhibitors prescribed in Korean patients , 2017, Pharmacoepidemiology and drug safety.
[12] M. Banach,et al. Intensive LDL‐cholesterol lowering therapy and neurocognitive function , 2017, Pharmacology & therapeutics.
[13] Gordon H Guyatt,et al. Introduction to BMJ Rapid Recommendations , 2016, British Medical Journal.
[14] C. Curtain,et al. Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors , 2016, Drug Safety.
[15] Zhenhao Piao,et al. Effects of Statins on Bone Mineral Density and Fracture Risk , 2016, Medicine.
[16] E. Liberopoulos,et al. Statin therapy with or without ezetimibe and the progression to diabetes. , 2016, Journal of clinical lipidology.
[17] G. Rosano,et al. Safety and efficacy of ezetimibe: A meta-analysis. , 2015, International journal of cardiology.
[18] Andrew E Moran,et al. Global and Regional Patterns in Cardiovascular Mortality From 1990 to 2013 , 2015, Circulation.
[19] A. Donzelli,et al. Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2015, PloS one.
[20] Bernadette A. Thomas,et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.
[21] R. Califf,et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.
[22] Ken-ichiro Tanaka,et al. Increased low-density lipoprotein cholesterol level is associated with non-vertebral fractures in postmenopausal women , 2015, Endocrine.
[23] P. Tugwell,et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .
[24] S. de Servi,et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. , 2013, The American journal of cardiology.
[25] P. Alagona,et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. , 2012, Journal of the American College of Cardiology.
[26] G. Franck. Open access , 2012, Cell cycle.
[27] Gordon H Guyatt,et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review , 2012, BMJ : British Medical Journal.
[28] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[29] M. Landray,et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.
[30] M. King. A point of minimal important difference (MID): a critique of terminology and methods , 2011, Expert review of pharmacoeconomics & outcomes research.
[31] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.
[32] S. Paisley,et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trials , 2009, Journal of internal medicine.
[33] J. Chambers,et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.
[34] P. Portincasa,et al. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. , 2008, Gastroenterology.
[35] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[36] J. Tu,et al. Use of ezetimibe in the United States and Canada. , 2008, The New England journal of medicine.
[37] R. Hays,et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. , 2008, Journal of clinical epidemiology.
[38] M. Willingham,et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. , 2007, The Journal of clinical investigation.
[39] R. Busch,et al. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[40] T. Musliner,et al. Striated muscle safety of ezetimibe/simvastatin (Vytorin). , 2006, The American journal of cardiology.
[41] J. Paolini,et al. Ezetimibe , 2005, Clinical pharmacokinetics.
[42] Luquan Wang,et al. Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption , 2022 .
[43] P. Thompson,et al. Statin-associated myopathy. , 2003, JAMA.
[44] R. Suresh,et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. , 2002, The American journal of cardiology.
[45] D. Tribble,et al. Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans , 2002, Circulation.
[46] I. Olkin,et al. Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .
[47] Е. П. Корнена,et al. Cholesterol lowering drugs. , 1993, The New Zealand medical journal.